Free Trial

CervoMed 11/12/2024 Earnings Report

CervoMed logo
$2.11 0.00 (0.00%)
As of 01/17/2025 04:00 PM Eastern

CervoMed EPS Results

Actual EPS
-$0.55
Consensus EPS
-$0.41
Beat/Miss
Missed by -$0.14
One Year Ago EPS
N/A

CervoMed Revenue Results

Actual Revenue
$1.94 million
Expected Revenue
$1.75 million
Beat/Miss
Beat by +$190.00 thousand
YoY Revenue Growth
N/A

CervoMed Announcement Details

Quarter
Time
Before Market Opens

Conference Call Resources

CervoMed Earnings Headlines

CervoMed downgraded to Neutral from Buy at H.C. Wainwright
Stunning Trump Exec Order Leaked
This secret document contains stunning details about Donald Trump’s very first order of business… the minute he steps back into the White House. Because if what’s in this leaked document is even half true (and trust me, it comes from a very, very credible source)...
CervoMed (CRVO) was downgraded to a Hold Rating at H.C. Wainwright
CervoMed announces inducement grants under Nasdaq lisitng rule
See More CervoMed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CervoMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CervoMed and other key companies, straight to your email.

About CervoMed

CervoMed (NASDAQ:CRVO), a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

View CervoMed Profile

More Earnings Resources from MarketBeat